Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.50 |
| ▸ | MAOA | P21397 | 12/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411101 | 0.87 | CALML3 (0.66) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL13944894 | 0.87 | CALML3 (0.50) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL412747 | 0.86 | CALML3 (0.56) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL412834 | 0.86 | GRM5 (0.37) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL411105 | 0.86 | CALML3 (0.51) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL13944916 | 0.86 | CALML3 (0.49) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL6625009 | 0.84 | MAOA (0.49) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL411618 | 0.84 | CALML3 (0.49) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL463725 | 0.83 | MAOA (0.50) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL442982 | 0.83 | MAOA (0.60) | CALML3MAOAMAOBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | CALML3 1652/4885MAOA 853/4885MAOB 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.